James Helliwell is the CEO of Eupraxia Pharmaceuticals, a clinical-stage biotechnology company focused on developing extended-release therapeutics.
James Helliwell is the CEO of Eupraxia Pharmaceuticals, a clinical-stage biotechnology company focused on developing extended-release therapeutics. Under his leadership, the company achieved key clinical milestones and became the first biotech to list exclusively on the Toronto Stock Exchange in nearly 20 years in 2021.
Full founder directory · Investor directory · Company funding database · Fundraising library